Shares of Mind Medicine Inc. (MNMD) surged more than 15% Friday afternoon, on track for their best session since April 2024, as retail traders cheered Robert F. Kennedy Jr.’s confirmation as U.S.

Patrick Trucchio has given his Buy rating due to a combination of factors that highlight the promising potential of Mind Medicine’s MM120 treatment. The company is advancing MM120, a ...

In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120 as a treatment for anxiety.

Mind Medicine (MindMed) has dosed the first subject in the Phase III Panorama study of a proprietary form of lysergide D-tartrate (LSD), MM120 orally disintegrating tablets (ODT), for the ...

The Panorama study will evaluate the efficacy and safety of MM120 ODT versus placebo, will be conducted in the United States and Europe, and is expected to enroll approximately 250 participants.

Mind Medicine (MNMD) announced that the first patient has been dosed in Panorama, its second Phase 3 study evaluating MM120 ODT, a proprietary, pharmaceutically optimized form of LSD for the ...

Voyage is the first of two Phase 3 studies in GAD evaluating the efficacy and safety of MM120 ODT Business Wire • last month MindMed Scientific Presentations at American College of ...

Panorama is the second Phase 3 trial of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 ...